Prescient Therapeutics announced the appointment of internationally renowned Australian haematologist and blood cancer researcher Professor H. Miles Prince AM to its Scientific Advisory Board (SAB). Professor Prince has contributed to the successful development of several new cancer therapies now in use worldwide. He is lead investigator in the Phase 1b trial of Prescient's targeted anti-cancer therapy, PTX-100, currently enrolling patients at Melbourne's Epworth Healthcare and Peninsula & South Eastern Haematology and Oncology Group. In addition to advancing revolutionary new targeted therapies like PTX-100, Professor Prince has pioneered the research and development of Chimeric Antigen Receptor T-cell (CAR-T) therapies in Australia.